Circulating Tumor DNA—the Potential of Liquid Biopsies

Karen Cravero; Ben Ho Park

doi:10.1007/s12609-016-0199-2

Circulating Tumor DNA—the Potential of Liquid Biopsies

Karen Cravero, Ben Ho Park

School of Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Recent studies suggest circulating cell-free tumor DNA offers advantages compared to tissue biopsies for mutation profiling. This concept of “liquid biopsy” allows for a more global genomic picture of metastatic disease since blood serves as a reservoir for all metastatic sites. In addition, cell-free tumor DNA can be measured quantitatively, presenting the possibility of using circulating tumor DNA as a biomarker to measure disease burden and response to therapies. Here, we review historic and recent studies demonstrating the clinical potential of measuring cell-free tumor DNA in breast cancer patients and future steps needed to translate liquid biopsies from research to clinical practice.

Original language	English (US)
Pages (from-to)	14-21
Number of pages	8
Journal	Current Breast Cancer Reports
Volume	8
Issue number	1
DOIs	https://doi.org/10.1007/s12609-016-0199-2
State	Published - Mar 1 2016

Keywords

Breast cancer
Circulating tumor DNA
Liquid biopsy
Mutation
Plasma tumor DNA
Translational research

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s12609-016-0199-2

Cite this

@article{b78edcc27709467680bbdfbc6524f535,

title = "Circulating Tumor DNA—the Potential of Liquid Biopsies",

abstract = "Recent studies suggest circulating cell-free tumor DNA offers advantages compared to tissue biopsies for mutation profiling. This concept of “liquid biopsy” allows for a more global genomic picture of metastatic disease since blood serves as a reservoir for all metastatic sites. In addition, cell-free tumor DNA can be measured quantitatively, presenting the possibility of using circulating tumor DNA as a biomarker to measure disease burden and response to therapies. Here, we review historic and recent studies demonstrating the clinical potential of measuring cell-free tumor DNA in breast cancer patients and future steps needed to translate liquid biopsies from research to clinical practice.",

keywords = "Breast cancer, Circulating tumor DNA, Liquid biopsy, Mutation, Plasma tumor DNA, Translational research",

author = "Karen Cravero and Park, {Ben Ho}",

year = "2016",

month = mar,

day = "1",

doi = "10.1007/s12609-016-0199-2",

language = "English (US)",

volume = "8",

pages = "14--21",

journal = "Current Breast Cancer Reports",

issn = "1943-4588",

publisher = "Current Science, Inc.",

number = "1",

}

TY - JOUR

T1 - Circulating Tumor DNA—the Potential of Liquid Biopsies

AU - Cravero, Karen

AU - Park, Ben Ho

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Recent studies suggest circulating cell-free tumor DNA offers advantages compared to tissue biopsies for mutation profiling. This concept of “liquid biopsy” allows for a more global genomic picture of metastatic disease since blood serves as a reservoir for all metastatic sites. In addition, cell-free tumor DNA can be measured quantitatively, presenting the possibility of using circulating tumor DNA as a biomarker to measure disease burden and response to therapies. Here, we review historic and recent studies demonstrating the clinical potential of measuring cell-free tumor DNA in breast cancer patients and future steps needed to translate liquid biopsies from research to clinical practice.

AB - Recent studies suggest circulating cell-free tumor DNA offers advantages compared to tissue biopsies for mutation profiling. This concept of “liquid biopsy” allows for a more global genomic picture of metastatic disease since blood serves as a reservoir for all metastatic sites. In addition, cell-free tumor DNA can be measured quantitatively, presenting the possibility of using circulating tumor DNA as a biomarker to measure disease burden and response to therapies. Here, we review historic and recent studies demonstrating the clinical potential of measuring cell-free tumor DNA in breast cancer patients and future steps needed to translate liquid biopsies from research to clinical practice.

KW - Breast cancer

KW - Circulating tumor DNA

KW - Liquid biopsy

KW - Mutation

KW - Plasma tumor DNA

KW - Translational research

UR - http://www.scopus.com/inward/record.url?scp=84960371279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960371279&partnerID=8YFLogxK

U2 - 10.1007/s12609-016-0199-2

DO - 10.1007/s12609-016-0199-2

M3 - Article

AN - SCOPUS:84960371279

SN - 1943-4588

VL - 8

SP - 14

EP - 21

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

IS - 1

ER -

Circulating Tumor DNA—the Potential of Liquid Biopsies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this